Table 1.
Characteristics of bisphosphonate users among persons with or without AD in the MEDALZ-2005 study
| All bisphosphonate users with AD % (n = 2920) | All bisphosphonate users without AD % (n = 3121) | p-value 0.001 | |
| Age | |||
| Mean (SD) | 80.84 (5.905) | 80.68 (5.729) | 0.103 |
| <75 | 13.3 (389) | 13.4 (417) | 0.964 |
| 75–79 | 25.3 (739) | 25.9 (808) | 0.605 |
| 80–84 | 34.3 (1003) | 35.6 (1111) | 0.309 |
| 85–89 | 21.4 (626) | 20.0 (623) | 0.157 |
| ≥90 | 5.3 (163) | 5.2 (162) | 0.500 |
| Female gender | 91.0 (2656) | 91.7 (2863) | 0.284 |
| Bisphosphonate | |||
| M05BA | 88.2 (2574) | 83.0 (2591) | <0.0001 |
| M05BB (Bisphosphonate+vitamin D) | 7.8 (227) | 11.2 (348) | |
| Both M05BA and M05BB | 4.1 (119) | 5.8 (182) | |
| Cumulative bisphosphonate use (with an opportunity to use) | (76%, n = 2226) | (78%, n = 2430) | |
| <one year | 32.1 (715) | 42.4 (1031) | <0.0001 |
| 1–3 years | 32.5 (701) | 24.1 (586) | |
| >3 to 5 years | 19.3 (430) | 16.3 (397) | |
| >5 years | 17.1 (380) | 17.1 (416) | |
| Charlson’s comorbidity index | |||
| 0 | 55.8 (1629) | 51.4 (1604) | <0.0001 |
| 1 | 31.4 (917) | 32.6 (1019) | |
| ≥2 | 12.8 (374) | 16.0 (498) | |
| Comorbidities | |||
| Asthma/COPD | 10.1 (295) | 13.4 (419) | <0.0001 |
| Diabetes | 9.5 (277) | 10.1 (315) | 0.428 |
| Rheumatoid arthritis | 7.9 (231) | 10.0 (321) | 0.005 |
| Cardiac insufficiency | 10.4 (305) | 11.6 (363) | 0.142 |
| Coronary heart disease | 22.9 (651) | 22.3 (7169) | 0.548 |
p-value: Persons with AD using bisphosphonates compared with persons without AD using bisphosphonates; chi-square.